Further Outpatient Care
Patients with a waxing and waning course of Mucha-Habermann disease require follow-up monitoring and additional treatment depending on the severity of the disease.
Regarding the questionable potential for malignant transformation, some authors have suggested that follow-up biopsy should be performed on lesions that last longer than 1 year and are refractory to treatment.
Deterrence/Prevention
No preventive methods have been identified.
Complications
Ulceronecrotic pityriasis lichenoides et varioliformis acuta (PLEVA) can lead to scarring.
Prognosis
No clear consensus has been formed regarding duration of the disease, but most cases tend to resolve over time.
Bowers S, Warshaw EM. Pityriasis lichenoides and its subtypes. J Am Acad Dermatol. Oct 2006;55(4):557-72; quiz 573-6. [Medline].
Fernandes NF, Rozdeba PJ, Schwartz RA, Kihiczak G, Lambert WC. Pityriasis lichenoides et varioliformis acuta: a disease spectrum. Int J Dermatol. Mar 2010;49(3):257-61. [Medline].
Panhans A, Bodemer C, Macinthyre E, Fraitag S, Paul C, de Prost Y. Pityriasis lichenoides of childhood with atypical CD30-positive cells and clonal T-cell receptor gene rearrangements. J Am Acad Dermatol. Sep 1996;35(3 Pt 1):489-90. [Medline].
Weiss LM, Wood GS, Ellisen LW, Reynolds TC, Sklar J. Clonal T-cell populations in pityriasis lichenoides et varioliformis acuta (Mucha-Habermann disease). Am J Pathol. Mar 1987;126(3):417-21. [Medline].
Magro C, Crowson AN, Kovatich A, Burns F. Pityriasis lichenoides: a clonal T-cell lymphoproliferative disorder. Hum Pathol. Aug 2002;33(8):788-95. [Medline].
Smith JJ, Oliver GF. Febrile ulceronecrotic Mucha-Habermann disease associated with herpes simplex virus type 2. J Am Acad Dermatol. Jan 2009;60(1):149-52. [Medline].
Panizzon RG, Speich R, Dazzi H. Atypical manifestations of pityriasis lichenoides chronica: development into paraneoplasia and non-Hodgkin lymphomas of the skin. Dermatology. 1992;184(1):65-9. [Medline].
Clayton R, Warin A. Pityriasis lichenoides chronica presenting as hypopigmentation. Br J Dermatol. Mar 1979;100(3):297-302. [Medline].
Boss JM, Boxley JD, Summerly R, Sutton RN. The detection of Epstein Barr virus antibody in 'exanthematic' dermatoses with special reference to pityriasis lichenoides. A preliminary survey. Clin Exp Dermatol. Mar 1978;3(1):51-6. [Medline].
Edwards BL, Bonagura VR, Valacer DJ, Ilowite NT. Mucha-Habermann's disease and arthritis: possible association with reactivated Epstein-Barr virus infection. J Rheumatol. Mar 1989;16(3):387-9. [Medline].
Andreev VC, Angelov N, Zlatkov NB. Skin manifestations in toxoplasmosis. Arch Dermatol. Aug 1969;100(2):196-9. [Medline].
Zlatkov NB, Andreev VC. Toxoplasmosis and pityriasis lichenoides. Br J Dermatol. Aug 1972;87(2):114-6. [Medline].
Rongioletti F, Rivara G, Rebora A. Pityriasis lichenoides et varioliformis acuta and acquired toxoplasmosis. Dermatologica. 1987;175(1):41-4. [Medline].
Nassef NE, Hammam MA. The relation between toxoplasmosis and pityriasis lichenoides chronica. J Egypt Soc Parasitol. Apr 1997;27(1):93-9. [Medline].
Ostlere LS, Langtry JA, Branfoot AC, Staughton RC. HIV seropositivity in association with pityriasis lichenoides et varioliformis acuta. Clin Exp Dermatol. Jan 1992;17(1):36-7. [Medline].
Smith KJ, Nelson A, Skelton H, Yeager J, Wagner KF. Pityriasis lichenoides et varioliformis acuta in HIV-1+ patients: a marker of early stage disease. The Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). Int J Dermatol. Feb 1997;36(2):104-9. [Medline].
Griffiths JK. Successful long-term use of cyclosporin A in HIV-induced pityriasis lichenoides chronica. J Acquir Immune Defic Syndr Hum Retrovirol. Aug 1 1998;18(4):396-7. [Medline].
Piamphongsant T. Tetracycline for the treatment of pityriasis lichenoides. Br J Dermatol. Sep 1974;91(3):319-22. [Medline].
Ackerman AB, Chongchitnant N, Sanchez J, et al. Histologic diagnosis of inflammatory skin diseases: an algorithmic method based on pattern analysis. 1997. Baltimore, Md: Lippincott Williams & Wilkins; 553-60.
Aydogan K, Saricaoglu H, Turan H. Narrowband UVB (311 nm, TL01) phototherapy for pityriasis lichenoides. Photodermatol Photoimmunol Photomed. Jun 2008;24(3):128-33. [Medline].
Pugashetti R, Koo J. Phototherapy in pediatric patients: choosing the appropriate treatment option. Semin Cutan Med Surg. Jun 2010;29(2):115-20. [Medline].
LeVine MJ. Phototherapy of pityriasis lichenoides. Arch Dermatol. May 1983;119(5):378-80. [Medline].
Panse I, Bourrat E, Rybojad M, Morel P. Photochemotherapy for pityriasis lichenoides: 3 cases. Ann Dermatol Venereol. 2004;131(2):201-3. [Medline].
Pavlotsky F, Baum S, Barzilai A, Shpiro D, Trau H. UVB therapy of pityriasis lichenoides--our experience with 29 patients. J Eur Acad Dermatol Venereol. May 2006;20(5):542-7. [Medline].
Powell FC, Muller SA. Psoralens and ultraviolet A therapy of pityriasis lichenoides. J Am Acad Dermatol. Jan 1984;10(1):59-64. [Medline].
Lazaridou E, Fotiadou C, Tsorova C, et al. Resistant pityriasis lichenoides et varioliformis acuta in a 3-year-old boy: successful treatment with methotrexate. Int J Dermatol. Feb 2010;49(2):215-7. [Medline].

